Latest Commercialisation News

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.

INOVIQ Limited has completed a $10.2 million capital raise to accelerate development of its exosome-based ovarian cancer screening test and CAR-exosome therapeutics, alongside key leadership appointments and promising preclinical results.

Prairie Lithium has secured a 10-year binding export agreement with South Korea’s Hydro Lithium and progressed key construction milestones at its Saskatchewan project, positioning itself as a rising player in North America’s lithium sector.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Acrux Limited reports solid revenue growth and increased cash reserves in the December quarter, driven by expanding its topical generics portfolio in the US and strategic moves into female Hormone Replacement Therapy.

Temas Resources has confirmed its patented Regenerative Chloride Leach (RCL) technology can produce commercial-grade titanium dioxide with significant cost reductions, positioning the company for global licensing opportunities.

Sea Forest Limited has exceeded its breakeven target for its methane-reducing feed additive SeaFeed™, securing commitments for over 118,000 cattle and expanding commercial trials with major industry partners.

NGX Limited has progressed its natural graphite exploration in Malawi and uranium projects in Namibia, while maintaining a robust financial footing with $2.7 million cash and no debt. The company is actively pursuing strategic partnerships and development pathways aligned with the clean energy transition.

Cleo Diagnostics has broadened its U.S. market opportunity to around 2 million women annually and is on track to complete its pivotal clinical trial early this year, supported by a $5 million capital raise and regulatory progress.

ImpediMed reported a solid Q2 FY26 with $3.9 million in revenue and significant reimbursement gains for its lymphoedema technology, while launching new US Heart Health and Wellness initiatives.

Vitrafy Life Sciences has marked significant progress in Q2 FY2026 with a strategic partnership, commercial launch in North America, and advancing clinical trials, underpinning its growth in cryopreservation technology.

Strategic Elements Ltd’s subsidiary Stealth Technologies has secured its inaugural commercial pilot deployment of the EdgeiQ system at an underground gold mine in Western Australia, marking a significant milestone in the technology’s commercialisation journey.